Highlights
A pilot randomized, double-blind, placebo-controlled clinical trial suggests that Sopoongsan (SPS) significantly reduces itching intensity (Numeric Rating Scale) in patients with chronic upper body pruritus associated with atopic or seborrheic dermatitis.
Translational research using DNCB-induced atopic dermatitis mouse models and HaCaT human epidermal keratinocytes confirms the anti-inflammatory and anti-atopic effects of SPS.
